303 related articles for article (PubMed ID: 30740404)
1. Fatty acid oxidation disorders.
Merritt JL; Norris M; Kanungo S
Ann Transl Med; 2018 Dec; 6(24):473. PubMed ID: 30740404
[TBL] [Abstract][Full Text] [Related]
2. Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders.
Sklirou E; Alodaib AN; Dobrowolski SF; Mohsen AA; Vockley J
Front Genet; 2020; 11():598760. PubMed ID: 33584796
[TBL] [Abstract][Full Text] [Related]
3. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening.
Kang E; Kim YM; Kang M; Heo SH; Kim GH; Choi IH; Choi JH; Yoo HW; Lee BH
BMC Pediatr; 2018 Mar; 18(1):103. PubMed ID: 29519241
[TBL] [Abstract][Full Text] [Related]
4. Long-chain fatty acid oxidation disorders and current management strategies.
Vockley J
Am J Manag Care; 2020 Aug; 26(7 Suppl):S147-S154. PubMed ID: 32840329
[TBL] [Abstract][Full Text] [Related]
5. Inborn Errors of Metabolism with Myopathy: Defects of Fatty Acid Oxidation and the Carnitine Shuttle System.
El-Gharbawy A; Vockley J
Pediatr Clin North Am; 2018 Apr; 65(2):317-335. PubMed ID: 29502916
[TBL] [Abstract][Full Text] [Related]
6. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review.
Vockley J; Marsden D; McCracken E; DeWard S; Barone A; Hsu K; Kakkis E
Mol Genet Metab; 2015; 116(1-2):53-60. PubMed ID: 26116311
[TBL] [Abstract][Full Text] [Related]
7. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.
Gillingham MB; Heitner SB; Martin J; Rose S; Goldstein A; El-Gharbawy AH; Deward S; Lasarev MR; Pollaro J; DeLany JP; Burchill LJ; Goodpaster B; Shoemaker J; Matern D; Harding CO; Vockley J
J Inherit Metab Dis; 2017 Nov; 40(6):831-843. PubMed ID: 28871440
[TBL] [Abstract][Full Text] [Related]
8. A review of fatty acid oxidation disorder mouse models.
Babcock SJ; Houten SM; Gillingham MB
Mol Genet Metab; 2024 May; 142(1):108351. PubMed ID: 38430613
[TBL] [Abstract][Full Text] [Related]
9. Heat stress deteriorates mitochondrial beta-oxidation of long-chain fatty acids in cultured fibroblasts with fatty acid beta-oxidation disorders.
Li H; Fukuda S; Hasegawa Y; Purevsuren J; Kobayashi H; Mushimoto Y; Yamaguchi S
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(20):1669-72. PubMed ID: 20207594
[TBL] [Abstract][Full Text] [Related]
10. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle.
Knottnerus SJG; Bleeker JC; Wüst RCI; Ferdinandusse S; IJlst L; Wijburg FA; Wanders RJA; Visser G; Houtkooper RH
Rev Endocr Metab Disord; 2018 Mar; 19(1):93-106. PubMed ID: 29926323
[TBL] [Abstract][Full Text] [Related]
11. Tutorial: Triheptanoin and Nutrition Management for Treatment of Long-Chain Fatty Acid Oxidation Disorders.
Norris MK; Scott AI; Sullivan S; Chang IJ; Lam C; Sun A; Hahn S; Thies JM; Gunnarson M; McKean KN; Merritt JL
JPEN J Parenter Enteral Nutr; 2021 Feb; 45(2):230-238. PubMed ID: 33085788
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of bezafibrate in two patients with mitochondrial trifunctional protein deficiency.
Suyama T; Shimura M; Fushimi T; Kuranobu N; Ichimoto K; Matsunaga A; Takayanagi M; Murayama K
Mol Genet Metab Rep; 2020 Sep; 24():100610. PubMed ID: 32509533
[TBL] [Abstract][Full Text] [Related]
13. Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management.
Shekhawat PS; Matern D; Strauss AW
Pediatr Res; 2005 May; 57(5 Pt 2):78R-86R. PubMed ID: 15817498
[TBL] [Abstract][Full Text] [Related]
14. Inborn Errors of Mitochondrial Fatty Acid Oxidation: Overview from a Clinical Perspective.
Yoo HW
J Lipid Atheroscler; 2021 Jan; 10(1):1-7. PubMed ID: 33537249
[TBL] [Abstract][Full Text] [Related]
15. Blood cytokine patterns suggest a modest inflammation phenotype in subjects with long-chain fatty acid oxidation disorders.
McCoin CS; Gillingham MB; Knotts TA; Vockley J; Ono-Moore KD; Blackburn ML; Norman JE; Adams SH
Physiol Rep; 2019 Mar; 7(6):e14037. PubMed ID: 30912279
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and Clinical Management of Long-chain Fatty-acid Oxidation Disorders: A Review.
Baker JJ; Burton BK
touchREV Endocrinol; 2021 Nov; 17(2):108-111. PubMed ID: 35118456
[TBL] [Abstract][Full Text] [Related]
17. Understanding patient, caregiver, and healthcare provider perspectives of the management of long-chain fatty acid oxidation disorders.
Baker ES; Botham J; Rechisky T; Romano E; Garcia D; Berry SA
Ther Adv Rare Dis; 2024; 5():26330040241252448. PubMed ID: 38778875
[TBL] [Abstract][Full Text] [Related]
18. Performance of serum and dried blood spot acylcarnitine profiles for detection of fatty acid β-oxidation disorders in adult patients with rhabdomyolysis.
Al-Thihli K; Sinclair G; Sirrs S; Mezei M; Nelson J; Vallance H
J Inherit Metab Dis; 2014 Mar; 37(2):207-13. PubMed ID: 23296367
[TBL] [Abstract][Full Text] [Related]
19. Clinical manifestations and management of fatty acid oxidation disorders.
Merritt JL; MacLeod E; Jurecka A; Hainline B
Rev Endocr Metab Disord; 2020 Dec; 21(4):479-493. PubMed ID: 32654032
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
